Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
DBV Technologies submitted a Biologics License Application to the U.S. FDA for the VIASKIN Peanut Patch for children ages 4 through 7 and requested Priority Review.Key Highlights:Original SEC Filing: DBV Technologies S.A. [ DBVT ] - 8-K - Sep. 29, 2026This is an AI-powered summary. It may contain i…
DBV Technologies SA said it submitted a Biologics License Application to the U.S. FDA for its Viaskin® peanut patch in children aged 4-7, requesting priority review.
DBV Technologies submitted a BLA to the FDA for its VIASKIN Peanut Patch in children aged 4-7, seeking Priority Review; the FDA previously granted Breakthrough Therapy designation.